COVID-19 and SARS-CoV-2 antibodies in multiple sclerosis patients: a large study in the Amsterdam MS Cohort

Completed

• Conditions: MS; multiple sclerosis; 10012303

• Registration Number: NL-OMON49502
• Lead Sponsor: Vrije Universiteit Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 750

Inclusion Criteria

Under current follow-up in the MS Center Amsterdam
Current diagnosis of multiple sclerosis
18 years or older

Exclusion Criteria

No informed consent

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Association of the course of COVID-19 and immunomodulatory treatment. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- establishing the percentage of MS patients who have currently developed<br /><br>SARS-CoV-2 antibodies in the Netherlands.<br /><br>- In the antibody positive patients we will associate disease course<br /><br>(asymptomatic, mild symptoms, severe symptoms, hospitalization) with MS<br /><br>characteristics, demographics and comorbidity.<br /><br>- Characteristics of patients with SARS-CoV-2 antibodies versus patients<br /><br>without antibodies in regards to demographics, MS characteristics,<br /><br>immunomodulatory treatments, prior medical history and degree of social<br /><br>isolation<br /><br>- With the Sanquin antibody test, we will study the antibody profile (IgM/G/A,<br /><br>IgG1/3) and repertoire (anti-SP, anti-NP).</p><br>